Back to results
US 2003/0225152 A1Published application
3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
OwnerSteven W. Andrews, Julie A. Wurster +1inventors
InventorsSteven W. Andrews, Julie A. Wurster, Clarence E. Hull, III
Life of this patent
Estimating the term…
Abstract
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
Claims11
A compound selected from the group consisting of
- 3-Phenylaminomethylene-1,3-dihydro-indol-2-one,
- 3-[(3-Bromo-phenylamino)-methylene]-1,3-dihydro-indol-2-one,
- 3-[(4-Bromo-phenylamino)-methyl]-1,3-dihydro-indol-2-one,
- 3-[(3-Bromo-phenylamino)-methyl]-1,3-dihydro-indol-2-one,
- 3-[(4-Ethyl-phenylamino)-methylene]-1,3-dihydro-indol-2-one,
- 3-Ethyl-phenylamino)-methylene]-1,3-dihydro-indol-2-one,
- 3-[(4-Methoxy-phenylamino)-methylene]-1,3-dihydro-indol-2-one,
- 4-[(2-Oxo-1,3-dihydro-indol-3-ylididenemethyl)-amino]-benzoic acid ethyl ester,
- 3-[(2-Ethyl-phenylamino)-methylene}-1,3-dihydro-indol-2-one,
- 3-[(3-Fluoro-4-methyl-phenylamino)-methylene]-1,3-dihydro-indol-2-one,
- 3-[(3-Fluoro-2-methyl-phenylamino)-methylene]-1,3-dihydro-indol-2-one,
- 3-[(4-Hydroxy-phenylamino)-methylene]-1,3-dihydro-indol-2-one,
- 3-[(3-Chloro-4-hydroxy-phenylamino)-methylene]-1,3-dihydro-indol-2-one,
- 3-[(4-Fluoro-2-methyl-phenylamino)-methylene]-1,3-dihydro-indol-2-one and pharmaceutically acceptable salts thereof.
11 more elements
A method for treating diseases related to unregulated tyrosine kinase signal transduction, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of
- 3-Phenylaminomethylene-1,3-dihydro-indol-2-one
- 3-[(3-Bromo-phenylamino)-methylene]-1,3-dihydro-indol-2-one
- 3-[(4-Bromo-phenylamino)-methyl]-1,3-dihydro-indol-2-one
- 3-[(3-Bromo-phenylamino)-methyl]-1,3-dihydro-indol-2-one
- 3-[(4-Ethyl-phenylamino)-methylene]-1,3-dihydro-indol-2-one
- 3-Ethyl-phenylamino)-methylene]-1,3-dihydro-indol-2-one
- 3-[(4-Methoxy-phenylamino)-methylene]-1,3-dihydro-indol-2-one
- 4-[(2-Oxo-1,3-dihydro-indol-3-ylididenemethyl)-amino]-benzoic acid ethyl ester
- 3-[(2-Ethyl-phenylamino)-methylene]-1,3-dihydro-indol-2-one
- 3-[(3-Fluoro-4-methyl-phenylamino)-methylene]-1,3-dihydro-indol-2-one
- 3-[(3-Fluoro-2-methyl-phenylamino)-methylene]-1,3-dihydro-indol-2-one
- 3-[(4-Hydroxy-phenylamino)-methylene]-1,3-dihydro-indol-2-one
- 3-[(3-Chloro-4-hydroxy-phenylamino)-methylene]-1,3-dihydro-indol-2-one
- 3-[(4-Fluoro-2-methyl-phenylamino)-methylene]-1,3-dihydro-indol-2-one and pharmaceutically acceptable salts thereof.
11 more elements
Dependencies are inferred from the claim text.